C.R. Bard (BCR) : 9 Wall Street analysts covering C.R. Bard (BCR) believe that the average level the stock could reach for the short term is $242.33. The maximum price target given is $264 and the minimum target for short term is around $232, hence the standard deviation is calculated at $10.45.
C.R. Bard (BCR) : 14 analysts are covering C.R. Bard (BCR) and their average rating on the stock is 2.79, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. C.R. Bard (BCR) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 12 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Also, Barclays maintains its rating on C.R. Bard (NYSE:BCR). The global brokerage major raises the current price target from $224 per share to $235 per share. Analysts at the Barclays have a current rating of Equalweight on the shares. The rating by the firm was issued on July 27, 2016.
C.R. Bard (NYSE:BCR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $220.91 and $218.22 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $221.72. The buying momentum continued till the end and the stock did not give up its gains. It closed at $221.50, notching a gain of 0.30% for the day. The total traded volume was 345,697 . The stock had closed at $220.84 on the previous day.
C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Companys vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.